3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Melanoma
4
Cholangiocarcinoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
Filgrastim
4
Ifosfamide
3
Carboplatin
3
Peripheral Blood Stem Cell Transplantation
2
Immune Checkpoint Inhibitors
2
Etoposide
2
spartalizumab
1
regorafenib
1
perifosine
1
pegfilgrastim
1
pazopanib
1
ivosidenib
1
etoposide phosphate
1
enasidenib
1
drozitumab
1
angiotensin I (1-7)
1
alanosine
1
abemaciclib
1
Vincristine
1
Trabectedin
1
Topotecan
1
Thiotepa
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiosurgery
1
Proton Therapy
1
Pharmacogenomic Testing
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Chondrosarcoma
×
regorafenib
×
Clear all
NCT02389244
2025-09-16
REGOBONE
UNICANCER
Phase 2
Active not recruiting
163 enrolled